Biotech finlandese-olandese spin-off di Aalto e Università di Helsinki che sviluppa terapie contro infezioni batteriche resistenti ai farmaci.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Seed Arivin Therapeutics closed a €3 million seed led by investor Michiel Seerden, with angels and non-dilutive funds from Business Finland, for its therapies against bacterial resistance. | $3.5M |